000			02024nas a22003495i 4500
001			1179-190X
003			DE-He213
005			20260610082520.0
007			cr nn 008mamaa
008			150723s||||||||sz uu poo|||||| b|EN |d
022			_a1179-190X
024	7		_a10.1007/40259.1179-190X _2doi
210	1	0	_aBioDrugs
245	1	0	_aBioDrugs _h[electronic resource] / _cedited by Mike Herbert.
264		1	_aCham : _bSpringer International Publishing : _bImprint: Adis.
300			_bonline resource.
520			_aBioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease. The Journal includes: Definitive reviews on topics relating to the development and use of biotechnology in healthcare and the management of disease. Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement. Original research articles on the clinical development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products. Leading/Current Opinion articles providing an overview of contentious or emerging issues and key regulatory and ethical issues. Adis Drug Evaluations reviewing the properties and place in therapy of biotechnology-based drugs. Adis Biosimilar Briefs summarizing key characteristics and clinical use of biosimilar drugs. .
650		0	_aMedicine—Research.
650		0	_aBiology—Research.
650		0	_aImmunospecificity.
650		0	_aCancer.
650		0	_aTherapeutics.
650	1	4	_aBiomedical Research.
650	2	4	_aAdaptive Immunity.
650	2	4	_aCancer Biology.
650	2	4	_aTherapeutics.
700	1		_aHerbert, Mike. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service)
776	0	8	_iPrinted version: _x1173-8804
856	4	0	_uhttps://doi.org/10.1007/40259.1179-190X _zHybrid
999			_c3534 _d3534